Posted by Michael Wonder on 01 Sep 2021
Jazz Pharmaceuticals announces Health Canada approval of Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
31 August 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Sunosi (solriamfetol) for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adult patients.
Once daily Sunosi is approved with doses of 75 mg and 150 mg.
